Recent Episodes
Watch recent episodes on
PTV News Review
Scroll Left
Scroll Right
Aisling Capital: How Funding Must Adapt to the Current Market




Episode Loading...




PharmaTelevision requires Javascript enabled and Adobe Flash Player to watch our programmes. If you do not have Flash installed, you can download it for free from the Adobe Flash homepage.

Improve your Internet experience and start watching exciting new video content.

Video title: Aisling Capital: How Funding Must Adapt to the Current Market
Released on: October 20, 2009. © PharmaVentures Ltd
Visitors: You are watching a 5 minute preview.
Share/save this page:
Email
Bookmark
Facebook
Twitter
LinkedIn
Follow us:
RSS
Twitter
  • Summary
  • Transcript
  • Participants
  • Company
In this interview, filmed at BioPharm in San Francisco, Dr Fintan Walton speaks with Dennis Purcell, Senior Managing Partner at Aisling Capital, an investment company dedicated to funding global healthcare companies.

They discuss:

• Dennis' experiences of the market's booms and slumps
• how funding has had to adapt
• bankruptcies and efficiency of capital
• how the funding model will change
• focusing on faster returns
• new alliances between Pharma and Biotech
Full video transcripts are available with PharmaTelevision Premium Content. Click here to buy a subscription or sign up for a 14 day free trial.
Dennis Purcell's experiences of the market's booms and slumps.
Fintan Walton:
Hello and welcome to PharmaTelevision News Review here in San Francisco at the BioPharm America Conference. On this show I have Dennis Purcell, who is the Senior Managing Partner at Aisling Capital based in New York. Welcome to the show.
Dennis Purcell:
Thank you. Thanks for having me.
Fintan Walton:
Dennis Purcell, these days in 2009 a company with fund investing in biotechnology must be interesting times?
Dennis Purcell:
They're challenging that's for sure. It's tough to raise capital because lot of our limited partners are struggling because of the market, and of course with the healthcare form coming up and with the melt down in the market it's a pretty challenging time.
Fintan Walton:
Okay. But your own background goes back over many years involved in the investment role both as an investment banker been in heading up various funds; how would you describe then 2009 relative to all the years experiences that you have had in investment business?
Full video transcripts are available with PharmaTelevision Premium Content. Click here to buy a subscription or sign up for a 14 day free trial.
Dennis Purcell
Senior Managing Partner
Mr. Dennis Purcell has served as the Senior Managing Partner of Fund I and Fund II since February 2000 and is responsible for the management of the Partnership. Prior to joining Fund I, Mr. Dennis Purcell served as Managing Director of the Life Sciences Investment Banking Group at Chase H&Q (formerly Hambrecht & Quist, H&Q) for over five years, and served on the Executive Committee of Hambrecht & Quist. While at Hambrecht & Quist, he was directly involved with over two hundred completed transactions and supervised over $10 billion of financing and advisory assignments in the pharmaceutical, biotechnology, and medical products industries. During his tenure, BioWorld and other industry publications cited H&Q as the leading underwriter of life sciences securities. Mr. Dennis Purcell has also often been cited as one of the sector's leaders. He was honored in the Biotech Hall of Fame by Genetic Engineering News and named to the Biotechnology All-Stars list by Forbes ASAP. Prior to joining H&Q, Mr. Dennis Purcell was a Managing Director in the Healthcare Group at PaineWebber, Inc. Mr. Dennis Purcell, at time of interview, currently serves as a director of Dynova Laboratories, Inc. and Xanodyne Pharmaceuticals, Inc. Previously he served as a director of Aton Pharmaceuticals, Inc., Auxilium Pharmaceuticals, Inc., Cengent Therapeutics, Inc., and Valentis, Inc. He is also a member of the Board of Directors of the Biotechnology Industry Organization (BIO) Emerging Companies Section. He has served as a member of the Advisory Council at Harvard Medical School.
Aisling Capital
Aisling Capital believes the next decade will be marked by a revolution in healthcare driven by new therapeutics generated by biotechnology. The completion of the human genome has given scientists new insights into the causes of human disease. These insights, combined with the past 20 years of developments in the biotechnology industry, are leading to rapid expansion of novel approaches toward the diagnosis, prevention, and treatment of life-threatening illnesses. These advances have led to an ever-increasing demand for capital to complete the development and commercialisation of new therapeutics. Aisling Capital's goal is to support the leading global healthcare companies that are building on these technical and medical breakthroughs to commercialise new healthcare products.